DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis

The concept of using BH3 mimetics as anticancer agents has been substantiated by the efficacy of selective drugs, such as Navitoclax and Venetoclax, in treating BCL-2-dependent haematological malignancies. However, most solid tumours depend on MCL-1 for survival, which is highly amplified in multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Milani, Mateus, Byrne, Dominic P, Greaves, Georgia, Butterworth, Michael, Cohen, Gerald M, Eyers, Patrick A, Varadarajan, Shankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386385/
https://www.ncbi.nlm.nih.gov/pubmed/28079887
http://dx.doi.org/10.1038/cddis.2016.485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386385/
https://www.ncbi.nlm.nih.gov/pubmed/28079887
http://dx.doi.org/10.1038/cddis.2016.485

Ejemplares similares